Alexander Schornstein
Alexander Schornstein's purchase track record
How the stock did after each of Alexander Schornstein's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/22/2024 | ASMB | $372K | -17.9% | -10.1% | -2.8% |
| 10/8/2024 | ASMB | $146K | +20.5% | -42.7% | -13.4% |
| 7/3/2024 | ASMB | $112K | +20.6% | +41.1% | +6.0% |
| 1/17/2024 | ASMB | $511K | +31.3% | +53.7% | +17.9% |
| 11/20/2023 | ASMB | $282K | +38.2% | +86.1% | +16.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Assembly Biosciences to Present Phase 1a ABI-6250 Data at AASLD 2026. Assembly Biosciences announced that it will share Phase 1a safety, tolerability and target engagement results for its liver‑focused candidate ABI‑6250 at the AASLD Liver Meeting 2026. The data will be the first clinical readout for the program and could provide insight into the drug’s early performance. The announcement comes as the stock trades near its recent support level.
Transaction History
| LITS | ▼ Sell | Open Market | 690,611 | $946K | 12/18/2025 | View on chart |
| ASMB | ▲ Buy | Open Market | 2,976 | $45K | 11/25/2024 | View on chart |
| ASMB | ▲ Buy | Open Market | 5,000 | $74K | 11/25/2024 | View on chart |
| ASMB | ▲ Buy | Open Market | 17,024 | $253K | 11/22/2024 | View on chart |
| ASMB | ▲ Buy | Open Market | 10,000 | $146K | 10/8/2024 | View on chart |
| ASMB | ▲ Buy | Open Market | 4,438 | $56K | 7/5/2024 | View on chart |
| ASMB | ▲ Buy | Open Market | 4,562 | $56K | 7/3/2024 | View on chart |
| ASMB | ▲ Buy | Open Market | 345,086 | $276K | 1/18/2024 | View on chart |
| ASMB | ▲ Buy | Open Market | 299,994 | $235K | 1/17/2024 | View on chart |
| ASMB | ▲ Buy | Open Market | 100,000 | $67K | 11/21/2023 | View on chart |
| ASMB | ▲ Buy | Open Market | 300,000 | $215K | 11/20/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Lite Strategy Reports Q4 EPS Improvement and Files Prospectus
Lite Strategy reported fourth-quarter earnings per share of $(0.38), an improvement from $(0.40) in the same period last year. The company also filed a prospectus for an offering of 1.889 million common shares on behalf of selling shareholders. These updates provide context for the stock's current trading range between $0.69 and $2.97.
Lite Strategy Reports Q4 EPS Improvement and Files Prospectus. Lite Strategy reported fourth-quarter earnings per share of $(0.38), an improvement from $(0.40) in the same period last year. The company also filed a prospectus for an offering of 1.889 million common shares on behalf of selling shareholders. These updates provide context for the stock's current trading range between $0.69 and $2.97.